QUARZAN

Pre-Launch

clidinium bromide

NDAORALCAPSULE
Lifecycle
Pre-Launch
Clinical Trials
20

Clinical Trials (5)

NCT05535972Phase 4Completed

To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

Started Oct 2022
463 enrolled
Pulmonary Disease, Chronic Obstructive
NCT03276052Phase 1Completed

A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants

Started Oct 2021
20 enrolled
Healthy Volunteers
NCT03181880Phase 4Withdrawn

To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease

Started Dec 2017
0
Chronic Obstructive Pulmonary Disease
NCT03276078Phase 2Completed

Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Started Nov 2017
20 enrolled
Pulmonary Disease, Chronic Obstructive
NCT03184987Phase 3Completed

A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma

Started Jun 2017
111 enrolled
Asthma